Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Current Medicinal Chemistry
Title: TRAIL: A Sword for Killing Tumors
Volume: 17 Issue: 29
Author(s): S. Wang
Affiliation:
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Export Options
About this article
Cite this article as:
Wang S., TRAIL: A Sword for Killing Tumors, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176285
DOI https://dx.doi.org/10.2174/092986710793176285 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Diagnosis and Treatment Guidance: Role of MRI and MRI Probes in the Era of Molecular Imaging
Current Pharmaceutical Biotechnology Micro-RNA Profiling as a Predictor of Clinical Outcomes for Head and Neck Cancer Patients
Current Pharmaceutical Design MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Development and In Vitro Proof-of-Concept of Interstitially Targeted Zinc- Phthalocyanine Liposomes for Photodynamic Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Current Research and Clinical Application in Head and Neck Radiotherapy)
Current Cancer Therapy Reviews Tumor Initiating Cells
Current Pharmaceutical Biotechnology Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Current Topics in Medicinal Chemistry The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype
MicroRNA Tirapazamine: From Bench to Clinical Trials
Current Clinical Pharmacology Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery Magnetic Resonance Imaging of Uncommon Hepatic Mesenchymal Tumours: Haemangioendothelioma and Angiosarcoma
Current Medical Imaging Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging